Convex Probe EBUS-guided Fiducial Placement for Malignant Central Lung Lesions

Simple item page
dc.contributor.authorMajid, Adnan
dc.contributor.authorPalkar, Atul
dc.contributor.authorKheir, Fayez
dc.contributor.authorAlape, Daniel
dc.contributor.authorFernández-Bussy, Sebastián
dc.contributor.authorAronovitz, Joseph
dc.contributor.authorGuerrero, Jorge
dc.contributor.authorGangadharan, Sidhu
dc.contributor.authorKent, Michael
dc.contributor.authorWhyte, Richard
dc.contributor.authorFolch, Erik
dc.date.accessioned2022-05-20T21:41:53Z
dc.date.available2022-05-20T21:41:53Z
dc.date.issued2018
dc.description.abstractBackground: Stereotactic body radiotherapy (SBRT) had become a therapeutic modality in patients with primary tumors, locally recurrent as well as oligometastasis involving the lung. Some modalities of SBRT require fiducial marker (FM) for dynamic tumor tracking. Previous studies have focused on evaluating bronchoscopic-guided FM placement for peripheral lung nodules. We describe the safety and feasibility of placing FM using real-time convex probe endobronchial ultrasound (CP-EBUS) for SBRT in patients with centrally located hilar/mediastinal masses or lymph nodes. Methods: This is a retrospective review of patients who were referred to Beth Israel Deaconess Medical Center’s multidisciplinary thoracic oncology program for FM placement to pursue SBRT. Results: Thirty-seven patients who underwent real-time CP-EBUS were included. Patients had a median age of 71 years [interquartile range (IQR), 59.5 to 80.5]. The median size of the lesion was 2.2 cm (IQR, 1.4 to 3.3 cm). The median distance from the central airway was 2.4 cm (IQR, 0 to 3.4 cm). A total of 51 FMs (median of 1 per patient) were deployed in 37 patients. At the time of SBRT planning, 46 (90.2%) were confirmed radiologically in 32 patients. Patients with unsuccessful fiducial deployment (n=5) underwent a second procedure using the same technique. Of those, 3 patients had a successful fiducial placement via bronchoscopy, 1 patient required FM placement by percutaneous computed tomography-guided approach and 1 patient required FM placement through EUS by gastroenterology. Conclusion: CP-EBUS-guided FM placement for patients with malignant lymph nodes and central parenchymal lung lesions appears to be safe and feasiblees
dc.description.versionVersión Publicadaes
dc.identifier.citationMajid, Adnan MD, FCCP*; Palkar, Atul MD*,†; Kheir, Fayez MD, MSCR*,‡; Alape, Daniel MD*; Fernandez-Bussy, Sebastian MD§; Aronovitz, Joseph MD, PhD∥; Guerrero, Jorge MD¶; Gangadharan, Sidhu MD*; Kent, Michael MD*; Whyte, Richard MD, MBA*; Folch, Erik MSc, MD# Convex Probe EBUS-guided Fiducial Placement for Malignant Central Lung Lesions, Journal of Bronchology & Interventional Pulmonology: October 2018 - Volume 25 - Issue 4 - p 283-289 doi: 10.1097/LBR.0000000000000497es
dc.identifier.urihttps://doi.org/10.1097/LBR.0000000000000497es
dc.identifier.urihttp://hdl.handle.net/11447/6119
dc.language.isoenes
dc.subjectUltrasonographyes
dc.subjectLunges
dc.subjectPathologyes
dc.titleConvex Probe EBUS-guided Fiducial Placement for Malignant Central Lung Lesionses
dc.typeArticlees
dcterms.sourceJournal of Bronchology & Interventional Pulmonologyes

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Convex_Probe_EBUS_guided_Fiducial_Placement_for.8.pdf
Size:
216.61 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services